,i  #aacth ,,congress  #b;d ,session    
,h4 ,r4 #ebad  ,,in ,,the ,,house ,,of  
,,representatives  ,july #bh1 #bjad ,mr4
 ,olson introduced the following bill2  
which was referred to the ,committee on 
,energy and ,commerce  ,a ,,bill  ,to   
require the ,secretary of ,health and   
,human ,services to provide for         
recommendations for the development and 
use of clinical data registries for the 
improvement of patient care4  #a4       
,recommendations for development and use
 of clinical data registries  7a7 ,in   
general ,not later than one year after  
the date of the enactment of this ,act1 
the ,secretary of ,health and ,human    
,services shall make recommendations for
 the development and use1 when          
appropriate1 of clinical data registries
 that are integrated with clinical      
practice guidelines and best practices  
or standards of care1 including         
registries designed to minimize         
duplication and burden on those         
operating or reporting to such          

registries1 for the improvement of      
patient care4 ,the ,secretary shall make
 such recommendations available to the  
public by posting them on a public      
,website of the ,department of ,health  
and ,human ,services4  7b7 ,specific    
recommendations ,such recommendations1  
with respect to such registries1 shall  
include the following3  7#a7            
,recommendations for a set of standards 
that1 if adopted by such registries1    
would allow for the bidirectional1      
interoperable exchange of information   
between the electronic health records of
 the reporting clinicians and such      
registries4  7#b7 ,recommendations on   
how clinical registries1 including      
outcomes-based registries1 may be       
developed and then used to evaluate     
various care models and methods1        
including improved clinical care        
coordination1 and the impact of such    
models and methods on the management of 
diseases as measured by appropriate care
 parameters based on clinical practice  

guidelines and best practices 7such as  
,a#a;,c1 blood pressure1 and cholesterol
 levels in the case of diabetes74  7#c7 
,recommendations on how such registries 
should be structured to facilitate the  
recording and reporting of post-market  
data for the purposes of monitoring     
safety and efficacy of ,,fda-approved   
devices and drugs1 reporting relevant   
clinical data to satisfy attestation    
requirements for coverage of prescribed 
devices and drugs1 and better defining  
appropriate clinical use in support of  
evidence development for the ,medicare  
program 7such as improving patient      
access to safe and effective glucose    
monitoring systems and future glucose   
monitoring technologies74  7#d7         
,recommendations on how data from such  
registries may be used to inform        
physicians and other health care        
professionals regarding clinical        
practices for the prevention of diseases
 7such as diabetes and the precursor    
conditions of diabetes7 and appropriate 

methods for the dissemination of        
clinical practice support tools and     
other educational resources that may be 
derived from registry data4  7#e7       
,recommendations for how registries can 
be used to promote preventive health    
benefits such as screenings and the     
,medicare annual wellness visits that   
may reduce the risk of chronic diseases 
7such as obesity1 osteoporosis1         
cardiovascular disease1 cancer1 diabetes
 and their complications74  7c7         
,consultation with clinical experts ,the
 ,secretary shall consult with national 
medical specialty societies and with    
manufacturers of drugs and medical      
devices in the development of such      
recommendations as they relate to the   
diseases that they 7or their            
manufactured drugs or devices7 manage   
and treat 7such as with endocrinologists
 with respect to recommendations        
relating to diabetes and pre-diabetes   
conditions74